Results 221 to 230 of about 1,649,588 (336)

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

open access: yesArthritis &Rheumatology, EarlyView.
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon   +28 more
wiley   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

open access: yesArthritis &Rheumatology, Accepted Article.
Summary Castleman disease (CD) is a major diagnostic challenge for Rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y.C. Chen   +2 more
wiley   +1 more source

Racial/Ethnic Disparities in Anticoagulation for Atrial Fibrillation by Sex and Within High and Low Stroke Risk Populations. [PDF]

open access: yesJ Innov Card Rhythm Manag
Tate WJ   +11 more
europepmc   +1 more source

Systemic autoimmune rheumatic disease risk is associated with long‐term exposure to fine particulate matter

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Fine particulate matter (PM2.5) is a possible trigger of systemic autoimmune rheumatic diseases (SARDs). We investigated SARDs risk related to long‐term exposure to PM2.5 and its components (ammonium, black carbon, mineral dust, sea salt, nitrate, sulfate, organic matter), the composition of which may affect toxicity.
Mareva Geslin   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy